March 30, 2017 - Three major national databases include varying estimates of racial gaps in the use of immediate breast reconstruction (IBR) after mastectomy for breast cancer, reports a study in the March issue of Plastic and Reconstructive Surgery®, the official medical journal of the American Society of Plastic Surgeons (ASPS).
All three databases report continued increases in the number of women benefiting from immediate breast reconstruction -- but with varying disparities among racial/ethnic minority patients. "Since these large databases play an important role in making healthcare policy, it's important to appreciate the significant differences in racial and socioeconomic disparities in IBR," comments ASPS Member Surgeon Samuel J. Lin, MD, MBA, of Harvard Medical School.
Variation in Disparities in Breast Reconstruction after Mastectomy
Dr. Lin and colleagues, including lead author Parisa Kamali, MD, analyzed data on IBR after mastectomy from three sources: the Agency for Healthcare Research & Quality's Nationwide Inpatient Sample (NIS) database, the American College of Surgeons' National Surgical Quality Improvement Project (NSQIP), and the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program. The analysis included data on approximately 1.2 million patients from 2005 to 2012.
During that time, all three databases reported significant increases in IBR after mastectomy. For women with invasive breast cancer, the percentage undergoing IBR increased from about 19 to 47 percent in the NIS, from 30 to 49 percent in the NSQIP, and from 12 to 25 percent in the SEER. Similar increases were seen among women with ductal carcinoma in situ (DCIS), a "pre-invasive" type of breast cancer.
Data from all three sources showed that white patients had the highest rate of IBR after mastectomy. In the NIS, the IBR rate was 35.7 percent in white women with invasive breast cancer versus 27.3 percent in black women, 30.8 percent in Hispanic women, and 30.5 percent in Asian women. In the NSQIP, the figures were generally similar: 43.1 percent, 30.7 percent, 40.3 percent, and 32.1 percent, respectively.
In contrast, the SEER data showed lower IBR rates in several categories: 20.6 percent in white women, 15.5 percent in black women, 12.9 percent in Hispanic women, and 14.0 percent in Asian women, respectively.
The disparities were similar among women with DCIS. The differences remained significant on subgroup analysis of data from California, where racial/ethnic disparities in IBR use ranged up to 50 percent.
While all three databases are viewed as representative of the US population, the researchers note some major variations between them. The NIS and NSQIP reflect practice patterns in nearly every state, while the SEER is limited to less than half of states. The SEER also lacks coverage of most of the major US cancer centers, including academic medical centers.
The study provides new insights amid continued concern over the lower rate of breast reconstruction among women of color. The ASPS played an active role in securing the passage of the Breast Cancer Patient Education Act of 2015, which sought to increase awareness of the availability of and insurance coverage for breast reconstruction--particularly among racial and ethnic minority patients.
"IBR utilization has increased significantly," Dr. Lin and coauthors write. "However, the extent of reporting of overall IBR rates and racial disparities differ significantly among databases." The authors believe that physicians, surgeons, and healthcare policy makers need to understand the strengths and weaknesses of the various databases in order to interpret the data.
"One database should not uniformly be utilized for clinical guidelines and policies," Dr. Lin and colleagues conclude. They add that the SEER "may not be universally generalizable to the entire US population."
Article: "Differences in the Reporting of Racial and Socioeconomic Disparities among Three Large National Databases for Breast Reconstruction" (doi: 10.1097/PRS.0000000000003207)
About Plastic and Reconstructive Surgery
For more than 70 years, Plastic and Reconstructive Surgery® has been the one consistently excellent reference for every specialist who uses plastic surgery techniques or works in conjunction with a plastic surgeon. The official journal of the American Society of Plastic Surgeons, Plastic and Reconstructive Surgery® brings subscribers up-to-the-minute reports on the latest techniques and follow-up for all areas of plastic and reconstructive surgery, including breast reconstruction, experimental studies, maxillofacial reconstruction, hand and microsurgery, burn repair, and cosmetic surgery, as well as news on medico-legal issues
The American Society of Plastic Surgeons is the largest organization of board-certified plastic surgeons in the world. Representing more than 7,000 physician members, the Society is recognized as a leading authority and information source on cosmetic and reconstructive plastic surgery. ASPS comprises more than 94 percent of all board-certified plastic surgeons in the United States. Founded in 1931, the Society represents physicians certified by The American Board of Plastic Surgery or The Royal College of Physicians and Surgeons of Canada.
About Wolters Kluwer
Wolters Kluwer N.V. (AEX: WKL) is a global leader in information services and solutions for professionals in the health, tax and accounting, risk and compliance, finance and legal sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with specialized technology and services.
Wolters Kluwer reported 2016 annual revenues of €4.3 billion. The company, headquartered in Alphen aan den Rijn, the Netherlands, serves customers in over 180 countries, maintains operations in over 40 countries and employs 19,000 people worldwide.
Wolters Kluwer shares are listed on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY).